Olema Pharmaceuticals, Inc.
(NASDAQ : OLMA)

( )
OLMA PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
MRKMerck & Co., Inc. 0.75%82.270.7%$1554.99m
JNJJohnson & Johnson 1.03%165.770.7%$1044.61m
PFEPfizer Inc. 0.90%43.540.9%$941.96m
ABBVAbbVie, Inc. 0.84%109.411.9%$659.88m
LLYEli Lilly & Co. 1.40%248.481.1%$639.12m
BMYBristol-Myers Squibb Co. 0.69%58.211.0%$634.93m
AZNAstraZeneca Plc 0.79%62.261.0%$284.98m
NVSNovartis AG 1.76%84.830.2%$182.69m
GSKGlaxoSmithKline Plc 0.88%40.160.2%$165.27m
AVIRAtea Pharmaceuticals, Inc. -2.59%12.390.3%$123.47m
RGENRepligen Corp. -0.31%273.836.8%$109.24m
NVONovo Nordisk A/S 1.14%107.380.1%$90.85m
VTRSViatris, Inc. -2.32%13.480.0%$89.53m
SNYSanofi 0.34%49.960.2%$66.44m
OGNOrganon & Co. -0.46%36.740.0%$53.17m

Company Profile

Olema Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of targeted therapies for women's cancers. The company also focuses on OP-1250, a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD) that is being studied in a Phase 1/2 clinical trial for the treatment of metastatic or locally advanced ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Olema Pharmaceuticals was founded by Cyrus L. Harmon and Peter J. Kushner on August 7, 2006 and is headquartered in San Francisco, CA.